Advertisement
New Zealand markets open in 9 hours 47 minutes
  • NZX 50

    11,627.86
    -54.53 (-0.47%)
     
  • NZD/USD

    0.6118
    -0.0002 (-0.04%)
     
  • ALL ORDS

    7,975.10
    -64.80 (-0.81%)
     
  • OIL

    81.10
    +0.37 (+0.46%)
     
  • GOLD

    2,336.90
    +5.70 (+0.24%)
     

Director Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)

On May 29, 2024, Thomas Kirk, Director at Myomo Inc (MYO), purchased 50,000 shares of the company, as reported in the SEC Filing. Following this transaction, the insider now owns a total of 236,499 shares of Myomo Inc. The shares were bought at a price of $3.5 per share, totaling $175,000.

Myomo Inc is a medical robotics company that specializes in myoelectric orthotics for people with neuromuscular disorders. The company's products help to restore function to weakened or paralyzed limbs.

Over the past year, Thomas Kirk has been actively increasing his stake in the company, purchasing a total of 150,000 shares and selling none. This recent acquisition further solidifies his investment in the company.

ADVERTISEMENT

The insider transaction history for Myomo Inc shows a trend of more insider buying than selling over the past year, with 8 insider buys and only 1 insider sell.

Shares of Myomo Inc were trading at $3.5 on the day of the transaction, giving the company a market cap of $98.258 million. According to the GF Value, the stock is currently significantly overvalued, with a price-to-GF-Value ratio of 5.

The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.

Director Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)
Director Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)
Director Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)
Director Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.